Wegovy vs Trulicity in Special Populations: A Head-to-Head Comparison

What Is Each Drug and How Do They Differ?

Wegovy and Trulicity both belong to the GLP-1 receptor agonist class, but they were engineered differently, carry different FDA indications, and were studied in largely non-overlapping patient populations. Understanding those differences is the foundation for any population-specific decision.

Mechanism and Molecular Design

Semaglutide (Wegovy) is a modified GLP-1 analogue with 94% homology to native GLP-1, extended by C18 fatty-diacid side-chain albumin binding that pushes its half-life to approximately 165 hours. That long half-life supports once-weekly dosing at 2.4 mg for weight management. Dulaglutide (Trulicity) is a GLP-1 analogue fused to a modified IgG4-Fc fragment, producing a half-life of roughly 90 hours. Both drugs activate the GLP-1 receptor in the hypothalamus, gut, and pancreatic beta cells, reducing appetite and slowing gastric emptying while stimulating glucose-dependent insulin secretion.

Approved Indications

Wegovy received FDA approval in June 2021 for chronic weight management in adults with a BMI <30 kg/m² or <27 kg/m² with at least one weight-related comorbidity, and in June 2023 for adolescents aged 12 and older with obesity. Trulicity is approved solely for glycemic control in type 2 diabetes and for reducing the risk of major adverse cardiovascular events (MACE) in adults with T2D who have established cardiovascular disease or multiple cardiovascular risk factors. Trulicity carries no FDA indication for weight management.

Titration Schedules

Both drugs require dose escalation to minimize GI adverse effects.

| Week | Wegovy (semaglutide) | Trulicity (dulaglutide) | |------|---------------------|------------------------| | 1 to 4 | 0.25 mg SC weekly | 0.75 mg SC weekly | | 5 to 8 | 0.5 mg SC weekly |, | | 9 to 12 | 1.0 mg SC weekly | 1.5 mg SC weekly (maintenance or advance) | | 13 to 16 | 1.7 mg SC weekly | 3.0 mg SC weekly (optional) | | 17+ | 2.4 mg SC weekly | 4.5 mg SC weekly (optional) |

Reaching the full 2.4 mg Wegovy dose takes 16 weeks. The FDA prescribing label for Wegovy allows the 1.7 mg dose to continue if the 2.4 mg is not tolerated.

Weight Loss Efficacy Across Populations

Weight reduction is the headline difference between these two agents.

STEP-1: Wegovy in Adults Without Diabetes

The STEP-1 trial enrolled 1,961 adults with obesity (BMI <30) or overweight (BMI <27) with a weight-related comorbidity but without type 2 diabetes. At 68 weeks, semaglutide 2.4 mg produced a mean weight loss of 14.9% versus 2.4% with placebo (P<0.001). Wilding et al., NEJM 2021 reported that 86.4% of participants receiving semaglutide lost at least 5% of body weight, compared with 31.5% on placebo.

STEP-2: Wegovy in Adults With Type 2 Diabetes

In STEP-2 (N=1,210), adults with T2D lost a mean of 9.6% body weight on semaglutide 2.4 mg versus 3.4% on placebo at 68 weeks. Weight loss was attenuated compared with STEP-1, consistent with the biology of insulin resistance limiting fat mobilization. Davies et al., Lancet 2021 confirmed statistically significant glycemic improvement alongside the weight benefit, with HbA1c falling 1.6 percentage points on the active drug.

AWARD-11: Trulicity's Best Weight Data

AWARD-11 (N=1,842 adults with T2D) compared dulaglutide 4.5 mg, 3.0 mg, and 1.5 mg weekly. The 4.5 mg arm achieved a 4.7 kg mean weight reduction at 36 weeks and an HbA1c reduction of 1.77 percentage points. Ludvik et al., Lancet 2021 showed dose-dependent improvement in both endpoints. That 4.7 kg figure translates to roughly 4 to 5% body weight for a typical participant, substantially less than Wegovy's 14.9%.

Practical Implication

For a patient whose primary goal is meaningful weight reduction (10% or more), the trial data support Wegovy as the stronger agent. For a patient whose primary goal is glycemic control with modest weight benefit, dulaglutide 4.5 mg offers a well-tolerated, equally convenient once-weekly option.

Cardiovascular Outcomes: Where Trulicity Stands Out

Both agents have dedicated cardiovascular outcomes trials, but the trial populations and results differ in clinically meaningful ways.

REWIND: Dulaglutide's Cardiovascular Edge

REWIND enrolled 9,901 adults with T2D, a mean age of 66.2 years, and critically, only 31.5% had prior cardiovascular disease. The majority had cardiovascular risk factors but no established ASCVD, making REWIND the first GLP-1 CVOT to show benefit in a predominantly primary-prevention population. At a median follow-up of 5.4 years, dulaglutide reduced the composite 3-point MACE endpoint (CV death, non-fatal MI, non-fatal stroke) by 12% relative to placebo (HR 0.88; 95% CI 0.79 to 0.99; P=0.026). Gerstein et al., Lancet 2019 also found a significant reduction in new-onset macroalbuminuria and a slower eGFR decline, hinting at renal benefit.

SUSTAIN-6: Semaglutide's Cardiovascular Trial

SUSTAIN-6 (N=3,297, median 2.1 years) tested semaglutide 0.5 mg and 1.0 mg (not the 2.4 mg Wegovy dose) in adults with T2D and high cardiovascular risk. Non-fatal stroke was reduced by 39% (HR 0.61; 95% CI 0.38 to 0.99), and non-fatal MI by 26% (HR 0.74; 95% CI 0.58 to 0.95). Marso et al., NEJM 2016 flagged a non-significant increase in diabetic retinopathy complications (3.0% vs 1.8%), which carries over as a label warning for all semaglutide formulations.

SELECT: Cardiovascular Data at the 2.4 mg Dose

The SELECT trial (N=17,604) tested semaglutide 2.4 mg in adults with established cardiovascular disease and obesity but without diabetes. At a mean follow-up of 34.2 months, MACE was reduced by 20% (HR 0.80; 95% CI 0.72 to 0.90; P<0.001). Lincoff et al., NEJM 2023 established the cardiovascular benefit of Wegovy's exact dose in a non-diabetic population, giving it a distinct edge for obese patients with prior ASCVD who do not have T2D.

Summary for CV Patients

• T2D with prior ASCVD, weight loss a priority: Wegovy (or oral semaglutide 14 mg, if eligible).
• T2D with mixed primary/secondary prevention profile: Trulicity has the most broadly applicable CVOT dataset.
• Obesity without T2D, prior ASCVD: SELECT data strongly favor Wegovy.

Renal Populations (CKD Stages 3 to 5)

Kidney disease changes the risk-benefit calculation for any drug that affects fluid balance, blood pressure, and glucose metabolism.

Pharmacokinetics in CKD

Neither semaglutide nor dulaglutide is primarily renally cleared. Both are metabolized via proteolytic cleavage in plasma and tissues; less than 3% of unchanged drug appears in urine for semaglutide. The FDA label for Wegovy states no dose adjustment is needed in patients with renal impairment, including end-stage renal disease. The same applies to Trulicity per its prescribing information.

Renal Outcomes Data

REWIND demonstrated a 15% relative risk reduction in new macroalbuminuria for dulaglutide (HR 0.85; 95% CI 0.77 to 0.93), representing one of the cleaner GLP-1 renal signals in a large CVOT. Gerstein et al., Lancet 2019 stratified participants by baseline renal function, showing consistent benefit across eGFR categories down to 15 mL/min/1.73 m².

A post-hoc analysis of STEP-2 showed that semaglutide 2.4 mg significantly reduced urine albumin-to-creatinine ratio versus placebo in T2D patients with varying degrees of renal impairment, though a dedicated renal outcomes trial (FLOW, testing semaglutide 1.0 mg in CKD) reported a 24% reduction in the composite kidney-failure endpoint. FLOW trial results, NEJM 2024 used the 1.0 mg dose, not 2.4 mg, so extrapolation to Wegovy requires caution.

GI Tolerability in CKD

Nausea-induced volume depletion is the main practical concern in CKD patients on GLP-1 agonists. Acute kidney injury from dehydration has been reported with the class. Providers should counsel patients on hydration and consider a slower-than-standard titration for CKD stage 3b or worse. The American Diabetes Association 2024 Standards of Care recommend GLP-1 agonists with proven cardiovascular or renal benefit as preferred agents in T2D patients with CKD, listing both dulaglutide and semaglutide.

Older Adults (Age 65 and Older)

Older patients carry unique risks: sarcopenia, fall risk from weight loss, polypharmacy, and frailty.

Weight Loss and Lean Mass

Approximately 25 to 39% of weight lost on GLP-1 agonists is lean mass rather than fat mass. In STEP-1, participants aged 65 and older lost proportionally similar total weight as younger adults, but the absolute lean-mass reduction raises concerns in patients with baseline sarcopenia. Cuthbertson et al., Obesity Reviews 2023 noted that resistance exercise combined with GLP-1 therapy can attenuate lean-mass loss.

Hypoglycemia Risk

When used as monotherapy or with metformin, neither agent causes clinically significant hypoglycemia in older adults. Risk rises substantially when either drug is combined with a sulfonylurea or insulin. The American Geriatrics Society Beers Criteria flag sulfonylureas as potentially inappropriate in older adults, and this interaction is worth resolving before initiating either GLP-1 agent.

Gastrointestinal Tolerability

Nausea occurs in roughly 44% of semaglutide 2.4 mg users during titration versus approximately 20% with dulaglutide 1.5 mg in controlled trials. Older adults, particularly those with gastroparesis or a history of GI motility disorders, may tolerate the dulaglutide titration more comfortably, though direct head-to-head GI tolerability data in patients over 65 are sparse.

Adolescents and Young Adults

Wegovy in Adolescents

The STEP TEENS trial (N=201, ages 12 to 17) showed semaglutide 2.4 mg produced a 16.1% reduction in BMI versus a 0.6% increase with placebo at 68 weeks. Wegman et al., NEJM 2022 led to FDA approval for Wegovy in adolescents aged 12 and older with obesity (BMI at or above the 95th percentile for age and sex).

Trulicity has no FDA-approved pediatric indication and no completed pediatric weight-management trials. For adolescents with obesity, Wegovy is the only weekly GLP-1 agonist with a label.

Women With PCOS or Premenopausal Obesity

Polycystic ovary syndrome (PCOS) affects 8 to 13% of reproductive-age women and carries obesity, insulin resistance, and ovulatory dysfunction as core features.

A useful clinical decision framework for GLP-1 selection in women with PCOS centers on three questions: Is conception being planned within 12 months? Is BMI reduction of 10% or more needed to restore ovulation? Does the patient also carry a T2D or prediabetes diagnosis? When the answer to the first question is no and the second is yes, Wegovy's superior weight-loss magnitude makes it the preferred starting point. When T2D is already present and the patient declines or cannot access Wegovy, dulaglutide 4.5 mg offers meaningful glycemic and modest weight benefit while maintaining once-weekly convenience.

Both drugs are contraindicated in pregnancy. The Wegovy label instructs discontinuation at least 2 months before a planned pregnancy. Providers managing women who might become pregnant should document this counseling and confirm contraceptive use.

The Endocrine Society 2023 clinical practice guideline on obesity pharmacotherapy specifies that GLP-1 agonists should be discontinued when pregnancy is confirmed and that weight-loss drugs in reproductive-age women require individualized contraception counseling.

Type 2 Diabetes Without Established Cardiovascular Disease

In this population, primary glycemic management and cardiometabolic risk factor reduction guide drug selection.

HbA1c Lowering

Across the AWARD series, dulaglutide 4.5 mg reduced HbA1c by 1.77 percentage points from a baseline of approximately 8.6% in AWARD-11. Semaglutide 1.0 mg (the Ozempic dose, not Wegovy) reduced HbA1c by 1.5 percentage points in SUSTAIN-7, where it outperformed dulaglutide 0.75 mg and 1.5 mg. The ADA 2024 Standards of Care recommend individualized HbA1c targets and prefer GLP-1 agonists with cardiovascular or weight-benefit data in T2D patients with BMI <27 kg/m².

Body Weight Goal Drives the Decision

If HbA1c is the primary concern and weight loss is secondary, either agent performs adequately at their highest doses. When a patient with T2D also has BMI <35 kg/m² and a target weight loss of 10% or more, Wegovy (used off-label alongside background T2D management or with a T2D diagnosis that satisfies Ozempic criteria) typically delivers a larger glycemic-plus-weight dividend. Prescribers should check payer coverage carefully: Wegovy is commonly excluded from formularies for patients who already qualify for Ozempic.

Switching Between Wegovy and Trulicity

Patients switch for several reasons: cost, GI intolerability, inadequate response, formulary change, or transition of care.

Switching FROM Wegovy TO Trulicity

The most common clinical scenario is a patient on Wegovy who loses insurance coverage or faces a supply disruption. The recommended approach is:

1. Determine the patient's current semaglutide dose.
2. Start dulaglutide 1.5 mg the week after the last semaglutide injection (no washout needed given overlapping GLP-1 activity).
3. Titrate dulaglutide to 3.0 mg or 4.5 mg after 4-week intervals if tolerated.
4. Expect partial weight regain. STEP-4 (N=803) showed that patients who discontinued semaglutide regained two-thirds of their lost weight within 1 year. Rubino et al., JAMA 2021 underscores why continuity on any GLP-1 agent is preferable to discontinuation.

Switching FROM Trulicity TO Wegovy

This switch is typically motivated by a desire for greater weight loss. Because Wegovy carries a distinct indication (weight management), patients without T2D who were on Trulicity off-label may find Wegovy better supported by payer criteria. Start semaglutide at 0.25 mg the week after the last dulaglutide dose and follow the standard 16-week titration. GI overlap during the first two weeks is possible but generally manageable.

What Patients Should Know

Weight regained after stopping Wegovy may not be fully recoverable on Trulicity alone. Setting realistic expectations before the switch prevents patient discouragement. Clinicians should document the reason for switching, the dose at transition, and the anticipated weight trajectory in the chart.

Safety Signals Common to Both Agents

Pancreatitis

Both carry an FDA class warning for acute pancreatitis. Patients with a history of pancreatitis should not use either drug. The absolute risk remains low: in REWIND, pancreatitis occurred in 0.6% of dulaglutide users versus 0.5% of placebo users, a non-significant difference. Gerstein et al., Lancet 2019.

Thyroid C-Cell Tumors

Both drugs carry a boxed warning for thyroid C-cell tumors based on rodent carcinogenicity data. Neither is recommended in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2. Human relevance remains unestablished; no clinical trial has identified an elevated human thyroid cancer rate for either drug.

Gallbladder Disease

Rapid weight loss from any cause increases cholelithiasis risk. In STEP-1, cholelithiasis occurred in 1.6% of semaglutide users versus 0.7% of placebo users. Patients with a history of gallstones should be counseled before starting Wegovy specifically.

Retinopathy (Semaglutide)

SUSTAIN-6 found a higher rate of diabetic retinopathy complications with semaglutide versus placebo (3.0% vs 1.8%; HR 1.76; 95% CI 1.11 to 2.78). This signal appears related to rapid glycemic improvement in patients with pre-existing retinopathy, not to direct retinal toxicity. Baseline ophthalmology evaluation is reasonable in T2D patients with known retinopathy before initiating semaglutide. Trulicity has no comparable retinopathy signal.